The CCF broadens its certification process guidelines to enable more CDMA vendors to benefit from standardized certification
SAN DIEGO, September 27, 2010 - Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
Telefonica Moviles Demonstrates the Fastest Download Speed on Commercial Dual-Carrier HSPA+ Network with Novatel Wireless' Ovation MC545
Bioartificial Liver Trial Now at Halfway Point SAN DIEGO, September 16, 2010 - Vital Therapies, Inc., (VTI) is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia (K.S.A.) in the further expansion of its SILVER (Stabilization In LiVER Failure) clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD(R), can prevent deterioration of liver function and improve the survival of subjects with acute-on-chronic liver failure (ACLF).
SAN DIEGO, September 16, 2010 - In the news release, Vital Therapies Expands SILVER Trial to Saudi Arabia, issued earlier today by Vital Therapies, Inc. over PR Newswire, we are advised by the company that the there are multiple changes to the release as originally issued inadvertently. Complete, corrected release follows:
Older News
31 1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
Copyright© 2010 The Gaea Times